Another type of COVID-19 vaccine was authorized by Health Canada on Friday. The new vaccines are manufactured by AstraZeneca, and developed in partnership with Oxford University. Canada also approved the Serum Institute of India’s version of the AstraZeneca vaccine.
Following Health Canada’s authorization of the AstraZeneca ChAdOx1 COVID-19 vaccine, Anita Anand the Minister of Public Services and Procurement announced that Canada has secured two million doses of the AstraZeneca COVID-19 vaccine through an agreement with Verity Pharmaceuticals Canada Inc./Serum Institute of India.
AstraZeneca has licensed the manufacture of its ChAdOx1 vaccine to the Serum Institute. The first 500,000 doses will be delivered to Canada in the coming weeks and will be ready for distribution to the provinces and territories.
The remaining 1.5 million doses are expected to arrive by mid-May.
“The Government of Canada continues to do everything possible to protect Canadians from COVID-19. This includes securing a highly diverse and extensive portfolio of vaccines and taking all necessary measures to ready the country to receive them,” Anand said in a release.
“We remain fully on track to ensure that there will be a sufficient supply so that every eligible Canadian who wants a vaccine will have access to one by the end of September. I am grateful for the collaboration of our partners in India to finalize this agreement, and I look forward to continuing to work closely together in the weeks ahead,” Minister of Public Services and Procurement Anita Anand
The two million doses secured through this agreement are in addition to the 20 million doses already secured through an earlier agreement with AstraZeneca. Health Canada’s authorization of the AstraZeneca vaccine allows the Government of Canada to advance its work with AstraZeneca to finalize delivery schedules for the 20 million doses.
The release explained that the announcement solidifies Canada’s plan to be able to provide a vaccine to everyone in Canada for whom these COVID-19 vaccines are recommended, by the end of September.
The application for authorization from AstraZeneca was received on Oct. 1, 2020 and from from Verity Pharmaceuticals Inc./Serum Institute of India (in partnership with AstraZeneca Canada Inc.) on January 23, 2021. After thorough, independent reviews of the evidence, the Department has determined that these vaccines meet Canada’s stringent safety, efficacy and quality requirements.
These are the first viral vector-based vaccines authorized in Canada. These are also two-dose regiments and can be kept refrigerated for at least six months.
Health Canada’s authorization of the Verity Pharmaceuticals Inc./Serum Institute of India product relies on the assessment of its comparability to the AstraZeneca-produced version of the vaccine..
These vaccines were authorized with terms and conditions under Health Canada’s Interim Order on the importation of drugs for COVID-19 The process allowed Health Canada to assess information submitted by the manufacturer as it became available during the product development process, while maintaining Canadian standards.
Health Canada has placed terms and conditions on the authorizations requiring the manufacturers to continue providing information to Health Canada on the safety, efficacy and quality of the vaccines to ensure their benefits continue to be demonstrated through market use.
Health Canada and the Public Health Agency of Canada will closely monitor the safety of vaccines once they are on the market and will not hesitate to take action if any safety concerns are identified.